|
Sign In to gain access to subscriptions and/or personal tools.
|
Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy
Gordon T McInnes
University of Glasgow, Department of Medicine and Therapeutics, Western Infirmary, Glasgow, G11 6NT, UK, g.t.mcinnes{at}clinmed.gla.ac.uk
Prospective randomised trials have demonstrated convincingly the benefits of drug treatment of hypertension. Treatment with conventional antihypertensive agents reduces the incidence of cardiovascular events by about that which would be expected from epidemiological data for the achieved difference in blood pressure. Newer agents, such as angiotensin II receptor blockers, have potential for benefits beyond blood pressure reduction. This rationale is under evaluation in a number of long-term morbidity and mortality trials which will report over the next few years, with the largest, VALUE, due to provide results in 2004. The findings from these trials will be decisive in determining the future role of this important new class of drugs.
Key Words: angiotensin receptor blockers coronary heart disease long-term mortality trials LIFE SCOPE valsartan VALUE
References
- Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994;50:272-98.[Abstract/Free Full Text]
- MacMahon S., Peto R., Cutler J. et al. Blood pressure, stroke, and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hansson L., Lindholm L., Niskanen L. et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hansson L., Lindholm LH, Ekbom T. et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-56.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.[Abstract/Free Full Text]
- McInnes GT, Hole D., Lever AF, Meredith PA, Murray LS, Reid JL ACE inhibitors and mortality at the Glasgow Blood Pressure Clinic. J Hum Hypertens 1999;13:897-8(abstract).
- McInnes G., Hole D., Lever A., Meredith P., Murray L., Reid J. Outcome differences between ACE inhibitor and calcium channel blocker treated hypertensive patients. J Hypertens 2000; 18(Suppl 4):S155(abstract).
- Julius S. Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan antihypertensive Long-term Use Evaluation. Cardiology 1999;91:8-13.[Web of Science][Medline]
[Order article via Infotrieve]
- Thürmann PA, Kenedi P., Schmidt A., Harder S., Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-42.[Abstract/Free Full Text]
- Staessen JA, Fagerd R., Thijs L. et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Guidelines Subcommittee. 1999 World Health Organisation - International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17: 151-83.[Web of Science][Medline]
[Order article via Infotrieve]
- Hansson L., Lithell H., Skoog I. et al. Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristics. Blood Press 2000;9:146-51.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Dahlof B., Devereux RB, Julius S. et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998;32:989-97.[Abstract/Free Full Text]
- CohenA., Bregman B.,Agabiti Rosei E. et al. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression. J Hum Hypertens 1998;12:479-83.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 2 suppl,
S17-S20 (2000)
DOI: 10.3317/jraas.2000.048

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|